ATF4 and cervical carcinoma: Bortezomib activates endoplasmic reticulum stress (ERS) in cervical cancer HeLa cells and promotes the expression of GRP78, ATF4 and CCAAT, and it induces autophagy and apoptosis in cervical cancer cells, thereby inhibiting cell proliferation, resulting in anticancer activity [66].